中国生物制药(01177.HK)拟1.1亿美元收购比利时呼吸道疾病设备提供商
格隆汇 3 月 23日丨中国生物制药(01177.HK)宣布,2021年3月22日,公司附属公司C-Lab International Limited订立协议以1.1亿美元作价,以及与监管和商业里程碑有关的额外付款收购100% SOFTHALE NV("Softhale")。Softhale是一家比利时私营公司,致力于开发用于治疗呼吸道疾病的产品。它的下一代软雾吸入设备("SMI")基于差异化技术,可以有效提高吸入药物的肺部沈积率。收购款项将由集团内部资源拨付。
事会认为,该收购具有以下战略意义,符合公司及其股东的利益:
1.通过研发下一代吸入器技术为慢性阻塞性肺炎("COPD")和哮喘患者提供更有效的药械合一产品,覆盖不同的COPD患者群体以补充集团现有的吸入药械产品组合覆盖范围,巩固集团在呼吸治疗领域的领先地位。
2.收购及全面控制在呼吸类疾病药物上的自主研发能力,推进集团从仿制到创新的转变。Softhale拥有的自主知识产权与专利将支持该SMI技术的应用与拓展,具实现结合新化合物╱药物并扩展到其他非呼吸治疗领域的潜力。3.通过在欧洲建立本地枢纽并开发具有重大全球市场潜力的产品,加快集团的国际化战略。
该收购中,集团聘请Results Healthcare(并购),Bakers Mc Kenzie(法律),Ernst & Young(财务和税务),Theraproval(监管)和Carpmaels & Ransford(知识产权)担任顾问。
董事会相信,Softhale将成为集团业务在欧洲发展的关键战略枢纽,并希望该公司发展为面向中国和全球市场的创新呼吸产品的领先开发商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.